Lv46
520 积分 2023-07-19 加入
Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory multiple myeloma
1天前
待确认
Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis
2天前
已完结
Multiple myeloma
4天前
已完结
Contemporary Management of Acute Myeloid Leukemia
10天前
已完结
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
10天前
已完结
Effects of consolidation therapy with autologous hematopoietic stem cell transplantation after BCMA-CAR T-cell therapy on the survival of patients with relapsed or refractory multiple myeloma
14天前
已完结
Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma
14天前
已完结
Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma
14天前
已关闭
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
16天前
已完结
OA-29 First results from the randomized portion of a phase 2 study of venetoclax plus carfilzomib-dexamethasone vs carfilzomib-dexamethasone in patients with t(11;14) relapsed/refractory multiple myeloma
17天前
已完结
皖公网安备34019202002308
